Viriathus Research Issues an Overview Report for Viralytics Limited

NEW YORK--()--Viriathus Research LLC, an independent research firm, issued an Overview Report today for Viralytics Limited (ASX: VLA) (OTC: VRACY) (BBSE: P10), a biotechnology company that is developing therapies and drugs for the treatment of cancer in Australia.

The report provides a description of Viralytics Limited’s business, industry, product, strategy, management team, and investment opportunities and risks.

The report is available free of charge at: www.viralytics.com/viriathus

About Viriathus Research LLC

Viriathus Research is a quality-leading New York based independent equity research company that provides insightful, in-depth research coverage and informational reports to emerging growth companies worldwide and the institutions that invest in them.

For further information on Viriathus Research, please visit www.viriathus.com/Research.htm

About Viralytics Limited

Viralytics Limited, is a biotechnology company developing therapies and drugs for the treatment of cancer in Australia. It primarily focuses on virotherapy treatment for a range of cancers, including melanoma, breast, and prostate. The company’s product portfolio comprises Coxsackievirus A21 (CVA21), a phase I clinical trial product for the treatment of melanoma; and CVA21 DAF, a phase I clinical trial product for the treatment of various human cancers. Viralytics also develops Echovirus-1, a pre-clinical trial product for the treatment of ovarian cancer. In addition, it offers SORAFIN, a proprietary platform technology for the treatment of skin diseases, which is a combination of auranofin combined with a corticosteroid. The SORAFIN-based products, which are in phase IIb trials, include Sorafin-P for the treatment of psoriasis; and Sorafin-AD for the treatment of atopic dermatitis. The company is based in Pymble, Australia.

For further information on Viralytics Limited, please visit www.viralytics.com.

Statement under the Private Securities Litigation Reform Act

With the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risk and uncertainties that may individually or mutually impact the matters herein described, including but not limited to the ability of the Company to increase revenues in the future due to the developing and unpredictable markets for its products, the ability to achieve a positive cash flow, the ability to obtain orders for or install its products, the ability to obtain new customers and the ability to continue to commercialize its products, which could cause actual results or revenues to differ materially from those contemplated by these statements.

Viriathus Research LLC received US$20,000 from the subject company in return for report authoring and distribution services.

Contacts

Viriathus Research LLC
Lisa Springer, +1 212 372 3116
lisa.springer@viriathus.com
www.viriathus.com
or
Viralytics Limited
Bryan Dulhunty, +61 2 9499 3200
Managing Director & CEO
www.viralytics.com

Contacts

Viriathus Research LLC
Lisa Springer, +1 212 372 3116
lisa.springer@viriathus.com
www.viriathus.com
or
Viralytics Limited
Bryan Dulhunty, +61 2 9499 3200
Managing Director & CEO
www.viralytics.com